Traveler’s Diarrhea Market Analysis, Epidemiology, Key Companies and Emerging Drugs

Traveler’s diarrhea (TD) is defined as ≥3 unformed stools in 24 hours accompanied by at least 1 of the following: fever, nausea, vomiting, cramps, tenesmus, or bloody stools (dysentery), in a traveler from a developed country visiting a less developed country. It is usually a benign self-limited illness lasting 3 to 5 days (mean 3.6 days).  Travelers’ diarrhea is caused by a variety of pathogens but most common bacteria is found in food and water, often related to poor hygiene practices in local restaurants. An estimated 30% to 70% of travelers experience travelers’ diarrhea, depending on where they go and what time of year. Countries are generally divided into 3 risk groups: high, intermediate, and low.


Visit For Sample Pages:


DelveInsight’s “Traveler’s Diarrhea Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Traveler’s Diarrhea, historical and forecasted epidemiology as well as the Traveler’s Diarrhea market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Traveler’s Diarrhea market report also covers emerging drugs, current treatment practices, Traveler’s Diarrhea market share of the individual therapies, current and forecasted Traveler’s Diarrhea Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current Traveler’s Diarrhea treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. 


Traveler’s Diarrhea Market Key Facts

  • DelveInsight’s estimates that the total incident population of Traveler’s Diarrhea in the UK was found to be 2,955,217 in 2017.
  • The diagnosed incident population of Traveler’s Diarrhea in the UK was 1,773,130 in 2017.
  • The severity of Traveler’s Diarrhea is categorized into mild, moderate and classical. There were 443,283 mild cases, 1,063,878 moderate cases and 265,970 cases of classical Traveler’s Diarrhea in 2017.
  • The EU5 (Germany, France, Italy, Spain and United Kingdom) countries account for 17,742,120 cases as a whole in 2017, out of which 16.6% of the total incident cases of Traveler’s Diarrhea is contributed by the UK itself.


Key Benefits of Traveler’s Diarrhea Market Report

  • Traveler’s Diarrhea market report provides an in-depth analysis of Traveler’s Diarrhea Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
  • The Traveler’s Diarrhea market report will help in developing business strategies by understanding the Traveler’s Diarrhea Market trends & developments, key players and future market competition that will shape and drive the Traveler’s Diarrhea market in the upcoming years.
  • The Traveler’s Diarrhea market report covers Traveler’s Diarrhea current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
  • The report provides a detailed assessment of the Traveler’s Diarrhea market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 


Traveler’s Diarrhea Market

The Traveler’s Diarrhea market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Traveler’s Diarrhea market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. 

The report gives a thorough detail of Traveler’s Diarrhea market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 


Traveler’s Diarrhea Epidemiology

The Traveler’s Diarrhea epidemiology section covers insights about historical and current Traveler’s Diarrhea patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  


Traveler’s Diarrhea Drugs Uptake and Key Market Players

The Traveler’s Diarrhea Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Traveler’s Diarrhea market or expected to get launched in the market during the study period. The analysis covers Traveler’s Diarrhea market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Key players in the Traveler’s Diarrhea market includes:

  • Procter and Gamble
  • Scandinavian Biopharma AB
  • Enteromed 
  • Cosmo Pharmaceuticals

And many others.


Visit For Sample Pages:


Table of Content

  1. Key Insights
  2. Executive Summary 
  3. Traveler’s Diarrhea Competitive Intelligence Analysis
  4. Traveler’s Diarrhea Market Overview at a Glance
  5. Traveler’s Diarrhea Disease Background and Overview
  6. Traveler’s Diarrhea Patient Journey
  7. Traveler’s Diarrhea Epidemiology and Patient Population
  8. Traveler’s Diarrhea Treatment Algorithm, Current Treatment, and Medical Practices
  9. Traveler’s Diarrhea Unmet Needs
  10. Key Endpoints of Traveler’s Diarrhea Treatment
  11. Traveler’s Diarrhea Marketed Products
  12. Traveler’s Diarrhea Emerging Therapies
  13. Traveler’s Diarrhea Seven Major Market Analysis
  14. Attribute Analysis
  15. Traveler’s Diarrhea Market Outlook (7 major markets)
  16. Traveler’s Diarrhea Access and Reimbursement Overview
  17. KOL Views on the Traveler’s Diarrhea Market.
  18. Traveler’s Diarrhea Market Drivers
  19. Traveler’s Diarrhea Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Related Reports-

Traveler’s Diarrhea Pipeline Insights, 2020

Traveler’s Diarrhea Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Traveler’s Diarrhea market.


Traveler’s Diarrhea Epidemiology Forecast to 2030

DelveInsight’s Traveler’s Diarrhea – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Traveler’s Diarrhea in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


Contact us:

Shruti Thakur

[email protected]